How have IMUCD shares performed in 2024?

ImmunoCellular Therapeutics' stock was trading at $0.2320 on January 1st, 2024. Since then, IMUCD shares have decreased by 35.3% and is now trading at $0.15. View the best growth stocks for 2024 here .

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IMUCD

ImmunoCellular Therapeutics (IMUCD) Stock Price, News & Analysis

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)

Free IMUCD Stock Alerts

$0.15

-0.05 (-25.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.15
▼
$0.20
50-Day Range: $0.13
▼
$0.30
52-Week Range: $0.16
▼
$0.51

Volume: 1,308 shs
Average Volume: 6,605 shs
Market Capitalization: $628,500.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get ImmunoCellular Therapeutics alerts:

Ad DTI

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.

IMUCD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMUCD Stock News Headlines

June 23, 2023 | finance.yahoo.com

RVVTF - Revive Therapeutics Ltd.

April 16, 2023 | thestreet.com

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

See More Headlines

Receive IMUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoCellular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:IMUCD
CUSIP: N/A
CIK: N/A
Web: www.imuc.com
Phone: (818) 264-2300
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,190,000
Free Float: N/A
Market Cap: $628,500.00
Optionable: Not Optionable
Beta: 1.63

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Gary S. Titus CPA (Age 60)
Independent Chairman & Corp. Sec.
Comp: $63k
Mr. Sanford J. Hillsberg (Age 71)
Co-Founder
Dr. John S. Yu (Age 56)
Founder & Director

Key Competitors

View All Competitors

IMUCD Stock Analysis - Frequently Asked Questions

How have IMUCD shares performed in 2024?: ImmunoCellular Therapeutics' stock was trading at $0.2320 on January 1st, 2024. Since then, IMUCD shares have decreased by 35.3% and is now trading at $0.15.
View the best growth stocks for 2024 here.
How do I buy shares of ImmunoCellular Therapeutics?: Shares of IMUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMUCD) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial